Cristina Gasparetto, MD, Duke University Medical Center

Articles by Cristina Gasparetto, MD, Duke University Medical Center

Teclistamab in RRMM: Patient Selection and Combining Therapies

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 28th 2022

Shifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.

BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 28th 2022

Focusing on relapsed/refractory MM, expert panelists review data from MajesTEC-1 and consider how bispecific antibodies are impacting the treatment paradigm.

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 21st 2022

Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease

Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 21st 2022

Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

ByCristina Gasparetto, MD, Duke University Medical Center

December 15th 2021

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.

Latest Updated Articles

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM
Published: July 21st 2022 | Updated:
BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab
Published: July 28th 2022 | Updated:
Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways
Published: July 21st 2022 | Updated:
Teclistamab in RRMM: Patient Selection and Combining Therapies
Published: July 28th 2022 | Updated:

Cristina Gasparetto, MD, Duke University Medical Center

Articles by Cristina Gasparetto, MD, Duke University Medical Center

Teclistamab in RRMM: Patient Selection and Combining Therapies

BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies